MUSTANG BIO, INC.

Analyst Reco. Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
0.26 ^USD	-3.77%		-18.19%	-80.74%

05-02	Mustang Bio, Inc. announced that it has received $3.3 million in funding	CI
04-30	Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	04-30	MT
BTIG Adjusts Price Target on Mustang Bio to $16 From $20, Maintains Buy Rating	15/08/23	MT
BTIG Raises Price Target on Mustang Bio to $20 From $4, Maintains Buy Rating	16/06/23	MT
B. Riley Adjusts Mustang Bio's Price Target to $10 From $4 After Model Updates, Reverse Stock Split; Keeps Buy Rating	30/05/23	MT
BTIG Adjusts Mustang Bio's Price Target to $4 From $8, Keeps Buy Rating	16/11/22	MT
Oppenheimer Adjusts Mustang Bio Price Target to $4 From $8, Maintains Outperform Rating	16/11/22	MT
B. Riley Securities Trims Mustang Bio's Price Target to $4 from $5, Keeps Buy Rating	14/07/22	MT
B. Riley Trims Mustang Bio's Price Target to $5 from $6 to Reflect Increased Long-Term Cost of Capital Amid Current Macro Conditions, Keeps Buy Rating	23/05/22	MT
B. Riley Lowers Mustang Bio's Price Target to $6 from $13 After Revising Cost Capital Assumptions, Keeps Buy Rating	24/01/22	MT
Mustang Bio Says Data From Cancer Treatment MB-106 Trial Shows Overall Response Rate of 95%	13/12/21	MT
Oppenheimer Adjusts Mustang Bio PT to $8 From $11, Maintains Outperform Rating	16/11/21	MT
MUSTANG BIO : BTIG Initiates Mustang Bio at Buy Rating With $11 Price Target	18/05/21	MT
MUSTANG BIO : Oppenheimer Adjusts Mustang Bio PT to $11 From $13, Maintains Outperform Rating	25/03/21	MT
MUSTANG BIO : B. Riley Reinstates Mustang Bio With Buy Rating, $13 Price Target	23/12/20	MT
MUSTANG BIO : B. Riley Adjusts Mustang Bio's Price Target to $13 From $9, Keeps Buy Rating	08/12/20	MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage	02/08/18	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer